Isis Pharmaceuticals (ISIS) announced that it will receive $7.5M from Alnylam Pharmaceuticals (ALNY) from the recently announced alliance between Genzyme, a Sanofi company (SNY), and Alnylam. In addition, Isis has the potential to receive royalties on products and a portion of future milestone payments. This transaction underscores the value of Isis' innovation and the leadership role Isis has played in the field of nucleic acid based therapeutics.
- Health Care Industry
- Alnylam Pharmaceuticals